Approved for the management of type 2 diabetes and obesity, GLP-1-RAs were shown in a 2021 Cochrane meta-analysis and systematic review to reduce the risk of all-cause mortality, cardiovascular mortality, and stroke [13]. This evidence concerns the gene GLP1R and obesity disorder.